Patent ID: 8790643
Filing Date: 2014-07-29
Classification: A61K,A61P,C07K,Y10S

Abstract:
1. A method of treating an inflammatory or autoimmune disease in a subject, wherein the disease is selected from the group consisting of an inflammatory bowel disease (IBD), systemic lupus erythematosus, rheumatoid arthritis, psoriasis, psoriatic arthritis, graft vs. host disease (GVHD), Sjogren's syndrome, scleroderma, and multiple sclerosis, the method comprising: administering to the subject a therapeutically effective amount of an anti-IL-21 receptor antibody, wherein said antibody is a humanized antibody derived from the monoclonal antibody produced by the hybridoma designated ATCC Accession NO. PTA-7141.